2021
DOI: 10.1016/j.csbj.2021.01.034
|View full text |Cite
|
Sign up to set email alerts
|

Chemokines and chemokine receptors during COVID-19 infection

Abstract: Graphical abstract

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

5
172
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 187 publications
(177 citation statements)
references
References 186 publications
5
172
0
Order By: Relevance
“…It does not appear that either of these approaches has been systematically investigated in COVID-19, ALI-ARDS or sepsis, and even the use of melatonin in COVID-19 was initiated in apparent ignorance of its multiple TLR/NLR-moderating effects. Since many individual TLR and NLR antagonists are being investigated, and some are in clinical trials, (reviewed in [267]), such multipronged therapies are quite feasible.…”
Section: Implications Of Innate Receptor Activation Profiles For Tretmentioning
confidence: 99%
See 1 more Smart Citation
“…It does not appear that either of these approaches has been systematically investigated in COVID-19, ALI-ARDS or sepsis, and even the use of melatonin in COVID-19 was initiated in apparent ignorance of its multiple TLR/NLR-moderating effects. Since many individual TLR and NLR antagonists are being investigated, and some are in clinical trials, (reviewed in [267]), such multipronged therapies are quite feasible.…”
Section: Implications Of Innate Receptor Activation Profiles For Tretmentioning
confidence: 99%
“…As noted in several places above (most notably in the Introduction and Section 2.8), interferon release is severely impaired in COVID-19, which facilitates SARS-CoV-2 infectivity and replication. A number of groups have therefore suggested, correctly in light of the IRAP model, that patients with severe COVID-19 need interferon supplementation [267][268][269][270][271][272], a therapeutic approach that would very likely be harmful in other cytokine release syndromes in which interferon is overproduced. An alternative suggested by the IRAP model might be to stimulate a natural interferon release using RIG1, NOD1 and, perhaps, TLR3 agonists (Figure 12).…”
Section: Implications Of Innate Receptor Activation Profiles For Tretmentioning
confidence: 99%
“…Step V. Activation and the disorganized immune response: Besides modifying cellular processes to support COVID-19 propagation, the stress responses to apoptosis triggered by an electrical and an electromagnetic radiation events activity may have deleterious consequences for the host cell leads to inflammatory in response to virus such as the cytokines, chemokines in plasma, and chemokine-receptor, and interfere with several receptors signaling pathway [6]. Because the COVID-19 seems is an electrically excitable virus has a structure that permits virus to pass chemical signal or an electrical signal to another virus or to the host cell that actively responds to effects some change brings it about and a stimulus such as B cell, T cells, Cytokine, chemokine, chemokine receptor, cytokines, and mast cell that (involved in the development of asthma or allergic rhinitis).…”
Section: Covid-19's Journey To and Interaction With The Host Cellsmentioning
confidence: 99%
“…As known COVID-19 is adept at evasion host immune responses [4] and interfere with several receptor signaling pathways such as chemokine receptors to produce an active inflammatory response [5,6]. Our previous work has shown the electrical properties of COVID-19 [7].…”
Section: Introductionmentioning
confidence: 99%
“…Effective treatments are required for COVID-19 hyperinflammatory syndrome, occurring characteristically 7-14 days after first symptoms (1) and variously described as "macrophage activation syndrome" (2), "cytokine storm" (3) or "acute respiratory distress syndrome" (4). Its immunological hallmarks are excessive elevation of predominantly proinflammatory cytokines, chemokines (5), and other bioactive molecules, such as HMGB1 (6) and reactive oxygen species (7). Upregulated cytokines include IL-6, TNF-α, IFN-γ, IL-1β, IL-15, IL-23, and IL-10, and chemokines, CXCL8(IL-8), CXCL9(MIG), CXCL10(IP10), CCL2(MCP-1), CCL3(MIP-1α), CCL5(RANTES), CCL7(MCP-3), CCL8(MCP-2), CCL11(eotaxin-1), and CCL20(MIP-3α) (1,2,(8)(9)(10)(11).…”
Section: Introductionmentioning
confidence: 99%